MTOR and cancer: In an initial screen for tumor type sensitivity to triple PIM/PI3K/mTOR inhibition by IBL‐302, 707 cell lines derived from 47 different tumor types were tested by the Genomics of Drug Sensitivity in Cancer (GDSC) screening program (Yang et al, 2013).